HilleVax’s (HLVX) Neutral Rating Reiterated at HC Wainwright

HC Wainwright restated their neutral rating on shares of HilleVax (NASDAQ:HLVX) in a report released on Monday, Benzinga reports. They currently have a $2.00 price target on the stock.

HLVX has been the subject of a number of other research reports. JPMorgan Chase & Co. reiterated a neutral rating and issued a $5.00 price objective (down previously from $24.00) on shares of HilleVax in a report on Monday, July 8th. SVB Leerink cut HilleVax from an outperform rating to a market perform rating and cut their price target for the company from $28.00 to $2.00 in a report on Tuesday, July 9th. Stifel Nicolaus lowered HilleVax from a buy rating to a hold rating and lowered their price objective for the stock from $34.00 to $3.00 in a research note on Tuesday, July 9th. Guggenheim downgraded HilleVax from a buy rating to a neutral rating in a research note on Monday, July 8th. Finally, Leerink Partnrs cut shares of HilleVax from a strong-buy rating to a hold rating in a research report on Tuesday, July 9th. Six equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, the company has an average rating of Hold and an average target price of $9.20.

HilleVax Stock Performance

Shares of NASDAQ:HLVX opened at $1.68 on Monday. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.92 and a quick ratio of 10.92. HilleVax has a 1 year low of $1.55 and a 1 year high of $20.22. The firm has a market capitalization of $83.53 million, a PE ratio of -0.51 and a beta of 0.80. The business’s 50 day moving average price is $7.09 and its 200-day moving average price is $12.23.

HilleVax (NASDAQ:HLVX) last announced its earnings results on Thursday, August 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.10). As a group, equities research analysts expect that HilleVax will post -2.58 earnings per share for the current fiscal year.

Insider Buying and Selling at HilleVax

In other HilleVax news, Director Aditya Kohli sold 6,000 shares of HilleVax stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $14.73, for a total value of $88,380.00. Following the sale, the director now owns 764,878 shares in the company, valued at $11,266,652.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 71.10% of the company’s stock.

Institutional Investors Weigh In On HilleVax

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. EntryPoint Capital LLC purchased a new stake in HilleVax in the first quarter valued at $80,000. SG Americas Securities LLC purchased a new stake in shares of HilleVax in the 4th quarter valued at $139,000. Tidal Investments LLC purchased a new stake in shares of HilleVax in the 1st quarter valued at $207,000. abrdn plc purchased a new stake in shares of HilleVax in the 4th quarter valued at $433,000. Finally, Swiss National Bank raised its holdings in shares of HilleVax by 22.4% in the 4th quarter. Swiss National Bank now owns 38,200 shares of the company’s stock valued at $613,000 after buying an additional 7,000 shares during the period. Hedge funds and other institutional investors own 86.42% of the company’s stock.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.